Filings & corporate actions
77 results filed
CSVNext results · Q2 FY27
Expected 2 Nov 2026 – 14 Nov 2026
Estimate: filed 33–45 days after quarter end, last 5 times
Dividend
₹0.20 per share · last 18 Sept 2026
2026
- 18 SeptdividendDividend · ₹0.20 per share+0.3%
- 4 AugresultsResults · Q1 FY27 · consolidated and standalone+11.2%NSE
- 13 JulshareholdingShareholding · 30 Jun 2026+1.7%NSE
- 26 MayresultsResults · Q4 FY26 · consolidated and standalone-3.9%NSE
- 10 AprshareholdingShareholding · 31 Mar 2026+1.4%NSE
- 10 FebresultsResults · Q3 FY26 · consolidated and standalone-0.6%NSE
- 13 JanshareholdingShareholding · 31 Dec 2025-0.6%NSE
Reaction to results · all yearsrose on day 0 in 21 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 4 Aug 2026 | +11.2% | +6.2% | +61.9% | 11.3× |
| Q4 FY26 | 26 May 2026 | -3.9% | +2.3% | +21.0% | 2.2× |
| Q3 FY26 | 10 Feb 2026 | -0.6% | -3.0% | +0.9% | 1.2× |
| Q2 FY26 | 14 Nov 2025 | 0.0% | -6.9% | -10.3% | 1.5× |
| Q1 FY26 | 6 Aug 2025 | -6.7% | -13.1% | -8.0% | 5.1× |
| Q4 FY25 | 12 May 2025 | -0.3% | +4.1% | +7.3% | 0.9× |
| Q3 FY25 | 6 Feb 2025 | -2.3% | -17.3% | -25.3% | 0.7× |
| Q2 FY25 | 11 Nov 2024 | -0.6% | -8.8% | +10.1% | 0.9× |
| Q1 FY25 | 12 Aug 2024 | -1.1% | +18.0% | +60.4% | 1.6× |
| Q4 FY24 | 21 May 2024 | +6.8% | -1.4% | +13.8% | 7.9× |
| Q3 FY24 | 31 Jan 2024 | +0.4% | +2.1% | -6.2% | 3.9× |
| Q2 FY24 | 2 Nov 2023 | +2.3% | +8.8% | +27.3% | 1.9× |
| Q1 FY24 | 5 Aug 2023 | +8.4% | +17.2% | +31.0% | 10.0× |
| Q4 FY23 | 16 May 2023 | -3.1% | -5.2% | +2.8% | 1.1× |
| Q3 FY23 | 13 Feb 2023 | -1.5% | -3.8% | -9.2% | 0.5× |
| Q2 FY23 | 10 Nov 2022 | +0.2% | +1.4% | +7.4% | 0.8× |
| Q4 FY22 | 5 May 2022 | -3.2% | -5.4% | -3.5% | 1.1× |
| Q3 FY22 | 8 Feb 2022 | -0.8% | -5.4% | -11.9% | 1.1× |
| Q2 FY22 | 12 Nov 2021 | -2.4% | -10.1% | +7.7% | 0.7× |
| Q1 FY22 | 27 Jul 2021 | -2.6% | -9.0% | -24.1% | 0.6× |
| Q4 FY21 | 4 May 2021 | -5.0% | -11.6% | -9.4% | 0.1× |
| Q3 FY21 | 12 Feb 2021 | -0.8% | -3.2% | +18.0% | 0.9× |
| Q2 FY21 | 9 Nov 2020 | -7.4% | -6.3% | +5.7% | 2.3× |
| Q1 FY21 | 31 Aug 2020 | -2.3% | -9.3% | -16.2% | 1.3× |
| Q4 FY20 | 22 Jun 2020 | -7.0% | -22.8% | -26.0% | 1.1× |
| Q3 FY20 | 14 Feb 2020 | +2.8% | -5.2% | -37.4% | 2.5× |
| Q2 FY20 | 13 Nov 2019 | -0.9% | +3.7% | -7.6% | 1.3× |
| Q1 FY20 | 13 Aug 2019 | -3.3% | -13.9% | +1.7% | 1.5× |
| Q4 FY19 | 7 May 2019 | -0.7% | -13.6% | -6.1% | 2.2× |
| Q3 FY19 | 11 Feb 2019 | -0.9% | -7.9% | +11.1% | 0.7× |
| Q2 FY19 | 22 Nov 2018 | -1.1% | -0.2% | +1.8% | 0.9× |
| Q1 FY19 | 23 Aug 2018 | -1.9% | +0.7% | -19.5% | 0.3× |
| Q4 FY18 | 25 May 2018 | +4.8% | -2.3% | +3.8% | 0.9× |
| Q3 FY18 | 24 Jan 2018 | -1.3% | -16.4% | -6.1% | 0.4× |
| Q2 FY18 | 22 Nov 2017 | +6.7% | +8.4% | +63.2% | 2.4× |
| Q1 FY18 | 22 Sept 2017 | -4.4% | -6.4% | -1.8% | 0.9× |
| Q4 FY17 | 16 Jun 2017 | -0.5% | -4.9% | -4.6% | 0.5× |
| Q3 FY17 | 11 Feb 2017 | -3.4% | +0.7% | -6.9% | 1.0× |
| Q2 FY17 | 9 Nov 2016 | +1.5% | -12.2% | -3.4% | 1.8× |
| Q1 FY17 | 21 Sept 2016 | -1.0% | +9.6% | +2.5% | 0.8× |
| Q4 FY16 | 11 May 2016 | +1.1% | -8.3% | -10.6% | 1.1× |
| Q3 FY16 | 13 Feb 2016 | -3.6% | -6.4% | -9.4% | 0.6× |
| Q2 FY16 | 6 Nov 2015 | +8.0% | +25.9% | +37.5% | 2.0× |
| Q1 FY16 | 10 Aug 2015 | -5.9% | -4.7% | -29.6% | 1.6× |
| Q3 FY15 | 20 May 2015 | -4.9% | -11.9% | -13.6% | 1.2× |
| Q4 FY15 | 20 May 2015 | -4.9% | -11.9% | -13.6% | 1.2× |
| Q2 FY15 | 21 Nov 2014 | -4.9% | -17.7% | -23.5% | 1.0× |
| Q1 FY15 | 14 Aug 2014 | +9.8% | +37.3% | +152.0% | 2.5× |
| Q4 FY14 | 27 May 2014 | -4.6% | -9.2% | -11.9% | 0.8× |
| Q3 FY14 | 17 Feb 2014 | +4.1% | -1.4% | +4.1% | 0.5× |
| Q2 FY14 | 26 Nov 2013 | -3.3% | +10.0% | +25.0% | 1.3× |
| Q1 FY14 | 6 Aug 2013 | +2.4% | +14.3% | +28.6% | 0.4× |
| Q4 FY13 | 17 May 2013 | -3.5% | -3.5% | -12.3% | 0.9× |
| Q3 FY13 | 12 Feb 2013 | -1.5% | -2.9% | -14.7% | 1.4× |
| Q2 FY13 | 5 Nov 2012 | -1.4% | -2.7% | +2.7% | 0.7× |
| Q1 FY13 | 6 Aug 2012 | -2.5% | -6.3% | -12.7% | 2.4× |
| Q4 FY12 | 15 May 2012 | 0.0% | -1.7% | +1.7% | 1.3× |
| Q3 FY12 | 10 Feb 2012 | +4.2% | +8.3% | +4.2% | 1.1× |
| Q2 FY12 | 9 Nov 2011 | -1.4% | -16.2% | -10.8% | 0.5× |
| Q1 FY12 | 8 Aug 2011 | -1.2% | -6.2% | -1.2% | 1.1× |
| Q4 FY11 | 13 May 2011 | -1.0% | -4.9% | -3.9% | 0.3× |
| Q3 FY11 | 11 Feb 2011 | -0.8% | -6.6% | -10.7% | 0.9× |
| Q2 FY11 | 1 Nov 2010 | 0.0% | 0.0% | -4.0% | 0.6× |
| Q1 FY11 | 30 Jul 2010 | -0.7% | -1.4% | -9.7% | 0.9× |
| Q4 FY10 | 13 May 2010 | -5.7% | -11.5% | -12.6% | 0.9× |
| Q3 FY10 | 21 Jan 2010 | -4.2% | -6.8% | -19.3% | 0.9× |
| Q2 FY10 | 27 Oct 2009 | -2.5% | -8.8% | +12.6% | 0.7× |
| Q1 FY10 | 31 Jul 2009 | -0.6% | -1.2% | +1.2% | 1.2× |
| Q4 FY09 | 27 May 2009 | +5.0% | +35.4% | +8.1% | 1.8× |
| Q3 FY09 | 20 Jan 2009 | -2.5% | -7.4% | -15.7% | 0.1× |
| Q2 FY09 | 22 Oct 2008 | -2.9% | -6.6% | -22.1% | 0.5× |
| Q1 FY09 | 24 Jul 2008 | -3.9% | -1.3% | -7.3% | 0.7× |
| Q4 FY08 | 16 May 2008 | +3.7% | -1.5% | -5.2% | 1.7× |
| Q3 FY08 | 15 Jan 2008 | -4.3% | -18.4% | -39.6% | 0.6× |
| Q2 FY08 | 18 Oct 2007 | -4.4% | -0.3% | +6.0% | 0.5× |
| Q1 FY08 | 18 Jul 2007 | +1.5% | -4.6% | +4.9% | 1.2× |
| Q4 FY07 | 30 Apr 2007 | +5.0% | +7.2% | +15.3% | 2.7× |
| Q3 FY07 | 5 Feb 2007 | +5.0% | -0.7% | -25.2% | 1.4× |
| Average | -0.7% | -2.5% | +1.0% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+34.1%
Profit YoY+424.7%
Interest cost YoY+53.3%
Revenue QoQ+17.6%
Profit QoQ+258.2%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +5.7% | +8.8% | — | +8.2% | +13.6% | +13.4% |
| Profit | +9.3% | +43.4% | — | +5.4% | +20.9% | +22.4% |
Key data
CSVOpen135.70
Day range135.61 – 145.25
52-week range33.05 – 145.25
From 52w high-0.9%
RSI (14)76.0
ATR (14)7.50
Volume2.24Cr
Avg volume (20D)1.87Cr
Rel volume1.20×
Volatility (1Y)55.4%
Turnover₹322.8Cr
SMA 50 / 20099.37 / 57.62
Delivery percentage
Latest · 6 Oct 202626.1%
20-day avg28.1%
1-year avg36.8%
Percentile (own history)8th
Range7.8–100.0%
Sessions1,731
Over the last 20 sessions MOREPENLAB settled 28.1% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 36.8%, so recent sessions are running 8.7 points lower than usual. The latest session ranks higher than 8% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +6.41% | +19.26% | +22.57% | +135.27% | +280.75% | +194.58% |
Valuation
CSVMarket cap₹7,888 Cr
P/E (TTM)56.1
EPS (TTM)2.56
Shares outstanding54.79Cr
Listed24 Nov 1999
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 411.6 | 484.2 | 484.7 | 570.1 |
| YoY chg | -6.0% | +6.9% | +4.0% | +34.1% |
| Net profit (₹ Cr) | 40.9 | 27.5 | 15.7 | 56.4 |
| YoY chg | +17.3% | +3.1% | -22.5% | +424.7% |
| Net margin | 9.9% | 5.7% | 3.2% | 9.9% |
| EPS | 0.75 | 0.50 | 0.28 | 1.03 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 35.65% · public 64.35%2021-092026-06
- Promoter
- Public and others
- Promoter
- 35.65%
- Public
- 64.35%
- Promoter change
- 0.00 pp
- Filed
- 13 Jul 2026
- FII
- 1.46%
- DII
- 1.28%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 421.8 | 444.6 | 423.1 | 455.2 | 437.7 | 452.8 | 465.9 | 425.2 | 411.6 | 484.2 | 484.7 | 570.1 | |
| Other income | 3.2 | 4.1 | 4.2 | 3.4 | 5.0 | 5.3 | 4.6 | 4.4 | 4.6 | 3.8 | 8.5 | 5.2 | |
| Total income | 425.0 | 448.6 | 427.3 | 458.6 | 442.7 | 458.1 | 470.5 | 429.6 | 416.2 | 488.0 | 493.2 | 575.3 | |
| Total expenses | 396.3 | 404.6 | 385.1 | 410.5 | 396.7 | 422.9 | 444.8 | 414.1 | 396.3 | 452.5 | 469.9 | 500.8 | |
| └ Finance costs | 0.5 | 2.2 | 0.8 | 1.2 | 1.2 | 1.3 | 4.7 | 4.0 | 4.2 | 4.3 | 3.9 | 4.8 | |
| └ Depreciation | 7.7 | 8.4 | 9.6 | 5.7 | 1.9 | 4.9 | 16.5 | 9.0 | 11.3 | 10.4 | 5.7 | 8.3 | |
| Profit before tax | 28.7 | 44.0 | 42.2 | 48.2 | 46.0 | 35.2 | 25.7 | 15.5 | 45.7 | 35.4 | 23.3 | 74.5 | |
| Tax expense | 7.4 | 12.0 | 13.5 | 12.0 | 11.2 | 8.5 | 5.4 | 4.1 | 4.7 | 7.9 | 7.6 | 18.2 | |
| Net profit | 21.3 | 32.0 | 28.3 | 36.2 | 34.8 | 26.7 | 20.3 | 10.7 | 40.9 | 27.5 | 15.7 | 56.4 | |
| EPS | 0.42 | 0.63 | 0.54 | 0.71 | 0.65 | 0.49 | 0.35 | 0.20 | 0.75 | 0.50 | 0.28 | 1.03 | |
| Net margin | 5.04% | 7.20% | 6.68% | 7.95% | 7.96% | 5.89% | 4.36% | 2.53% | 9.93% | 5.68% | 3.25% | 9.89% | |
| PBT margin | 6.80% | 9.90% | 9.98% | 10.58% | 10.51% | 7.78% | 5.52% | 3.65% | 11.10% | 7.32% | 4.80% | 13.07% | |
| Tax rate | 25.89% | 27.33% | 31.90% | 24.91% | 24.28% | 24.19% | 21.02% | 26.49% | 10.18% | 22.38% | 32.58% | 24.40% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 4 Aug 2026.
MOREPENLAB at a glance
- MOREPENLAB closed at ₹143.96 on 6 Oct 2026, +6.41% on the day, +194.6% over one year, 0.9% below its 52-week high of ₹145.25.
- Delivery was 26.1% of traded quantity on 6 Oct 2026, the 8th percentile of its own 1,731 sessions with a reading (20-session average 28.1%, 1-year average 36.8%).
- Market capitalisation is ₹7,888 crore at a trailing P/E of 56.1 (trailing EPS ₹2.56).
- Q1 FY27 results (consolidated, filed 4 Aug 2026): revenue ₹570 crore (+34.1% year on year), net profit ₹56 crore (+424.7%); the price moved +11.2% on the first session after.
- Promoters held 35.65% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 2 Nov 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE083A01026
SeriesEQ
Listed24 Nov 1999
History from15 May 1995
Sessions7,757
Turnover rank#121
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
- MANKINDMankind Pharma Limited2,500.00+0.85%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE